GlycoMimetics

GlycoMimetics is a biotechnology company with a focus on improving outcomes for patients with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Since its establishment in 2003, the company has been dedicated to advancing research and clinical candidates to deliver breakthrough treatments. Leveraging a deep understanding of carbohydrates' role in cell recognition processes, GlycoMimetics develops small molecule drugs, or glycomimetics, to alter carbohydrate-mediated recognition in various disease states, including cancer and inflammation. The company's expertise extends from research to late-stage clinical development, and it is a publicly traded company on the NASDAQ under the symbol GLYC. Its latest notable investment was a Post-IPO Equity investment on 28 September 2017.